Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 1:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 239 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ctDNA Clear all
Recruiting No phase listed Observational

ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC

NCT07332975
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Recruiting No phase listed Observational

Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial

NCT07726602
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Non-Interventional Study
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Not yet recruiting Phase 2 Interventional

[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)

NCT07723651
View directory record Official record
Conditions
Metastatic Prostate Cancer, Prostate Cancer
Interventions
1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one, FTT-PET/CT, EnhanceAR-Seq
Drug · Device · Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Recruiting Phase 2 Interventional

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

NCT06517212
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms, Breast Cancers
Interventions
Tirzepatide
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Recruiting Phase 2 Interventional

Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)

NCT06088381
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Experimental Observation, Observation per Standard of Care, Adjuvant Treatment per Standard of Care, Circulating Tumor DNA test (ctDNA test)
Other · Radiation · Diagnostic Test
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 26, 2026, 1:12 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study of Lung Cancer Screening in People With Unexplained Weight Loss

NCT06717334
View directory record Official record
Conditions
Lung Cancer Screening
Interventions
Low Dose CT imaging, blood draws, screening questionnaire
Diagnostic Test · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
50 Years to 80 Years
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Tebentafusp for Uveal Melanoma

NCT06414590
View directory record Official record
Conditions
Locally Advanced Unresectable Uveal Melanoma
Interventions
Tebentafusp-Tebn
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Withdrawn No phase listed Observational

A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation After Clinical Complete Response to Neoadjuvant Therapy for Rectal Cancer

NCT03749083
View directory record Official record
Conditions
Gastrointestinal Malignancies
Interventions
The Functional Assessment of Cancer Therapy- Colorectal
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Timeline
2019 – 2024
U.S. locations
4
States / cities
Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Oct 26, 2026, 1:12 PM EDT
Not yet recruiting Not applicable Interventional

Signatera Assessment in Early-Stage Endometrial Cancer

NCT07339384
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Signatera Genome ultra-sensitive ctDNA blood test
Device
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

The Circulating Cell-free Genome Atlas Study

NCT02889978
View directory record Official record
Conditions
Neoplasms, Cancer
Interventions
Not listed
Lead sponsor
GRAIL, Inc.
Industry
Eligibility
20 Years and older
Enrollment
15,254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
139
States / cities
Daphne, Alabama • Mobile, Alabama • Phoenix, Arizona + 105 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 26, 2026, 1:12 PM EDT
Terminated No phase listed Observational

Circulating Tumor DNA Alterations in Non-small Cell Lung Cancer Patients Treated With Pembrolizumab

NCT04791215
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Observational
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 26, 2026, 1:12 PM EDT
Terminated No phase listed Observational

Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients

NCT03594448
View directory record Official record
Conditions
Microsatellite Instability, Colorectal Cancer Stage IV
Interventions
Specimen Collection, Serial Liquid Biopsy
Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Los Angeles, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 26, 2026, 1:12 PM EDT
Not yet recruiting No phase listed Observational

Circulating Tumor DNA (ctDNA) in High Grade Upper Tract Urothelial Cancer (UTUC)

NCT07793240
View directory record Official record
Conditions
Upper Tract Urothelial Carcinoma
Interventions
Signatera testing
Diagnostic Test
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Not yet recruiting No phase listed Observational

Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer (MIBC)

NCT07893509
View directory record Official record
Conditions
NMIBC, MIBC, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer
Interventions
This is a non-interventional, observational, prospective study.
Other
Lead sponsor
Bladder Cancer Advocacy Network
Other
Eligibility
18 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Recruiting Phase 2 Interventional

HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

NCT07459673
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, Breast Cancer Stage IV
Interventions
Personalis NeXT Personal, Natera Signatera, fam-trastuzumab deruxtecan-nxki (T-DXd), pertuzumab, called T-DXd+P
Diagnostic Test · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Terminated No phase listed Observational

NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

NCT04698681
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Mutation, NFE2L2 Gene Mutation
Interventions
Not listed
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
63
States / cities
Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 26, 2026, 1:12 PM EDT
Active, not recruiting No phase listed Observational

Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy

NCT07122466
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Tumor DNA circulating in the bloodstream (circulating tumor DNA; ctDNA)
Diagnostic Test
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Active, not recruiting No phase listed Observational

Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma

NCT03896620
View directory record Official record
Conditions
Sarcoma
Interventions
Preoperative RT, Postoperative RT, Chemotherapy, Surgery
Device · Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Recruiting No phase listed Observational

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

NCT06401421
View directory record Official record
Conditions
Breast Cancer
Interventions
ctDNA MRD test
Diagnostic Test
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
53
States / cities
Anchorage, Alaska • Palo Alto, California • Torrance, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Not yet recruiting Phase 2 Interventional

ctDNA-Informed Management of Early-Stage Rectal Cancer

NCT07209215
View directory record Official record
Conditions
Rectal Adenocarcinoma, Rectal Cancer, Early-stage Rectal Cancer, Locally Advanced Rectal Adenocarcinoma
Interventions
Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT)
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 4 Interventional

Prospective Clinicogenomic Program

NCT04180176
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC), Small-Cell Lung Cancer (SCLC)
Interventions
Blood Draw
Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
945 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 26, 2026, 1:12 PM EDT
Not listed No phase listed Observational

BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

NCT04264702
View directory record Official record
Conditions
Colorectal Cancer, Colon Cancer
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,788 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Carlos, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 26, 2026, 1:12 PM EDT
Not yet recruiting Early Phase 1 Interventional

Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy

NCT06979661
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer, Lung Cancer Recurrent
Interventions
Haystack™ ctDNA Assay
Diagnostic Test
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 26, 2026, 1:12 PM EDT
Recruiting Not applicable Interventional

Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer

NCT06849518
View directory record Official record
Conditions
Lung Cancer (NSCLC)
Interventions
Circulogene liquid biopsy testing
Diagnostic Test
Lead sponsor
Ballad Health
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kingsport, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 26, 2026, 1:12 PM EDT